{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:37:29Z","timestamp":1787506649033,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.htct.2018.10.002","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T17:28:28Z","timestamp":1550510908000},"page":"119-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-3739","authenticated-orcid":false,"given":"Deivide Sousa","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeu G.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda L. Neri","family":"Benevides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna A. Tavares","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia P.","family":"Boris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herivaldo F.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2018.10.002_bib0170","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"key":"10.1016\/j.htct.2018.10.002_bib0175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/beha.2001.0142","article-title":"Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease","volume":"14","author":"Furlan","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.htct.2018.10.002_bib0180","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.htct.2018.10.002_bib0185","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0190","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/asheducation.V2012.1.604.3798564","article-title":"Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"2012","author":"George","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.htct.2018.10.002_bib0195","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood.V96.4.1223","article-title":"How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"96","author":"George","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0200","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1538-7836.2005.01425.x","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"L\u00e4mmle","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.htct.2018.10.002_bib0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.htct.2018.10.002_bib0210","doi-asserted-by":"crossref","first-page":"R273","DOI":"10.1186\/cc13115","article-title":"The prognostic value of ADAMTS13 deficiency in septic shock patients involves IL-6 and is not dependent on disseminated intravascular coagulation","volume":"17","author":"Peigne","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.htct.2018.10.002_bib0215","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.htct.2018.10.002_bib0220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/ajcp\/aqw003","article-title":"An algorithmic approach to the diagnosis and management of the thrombotic microangiopathies","volume":"145","author":"Bendapudi","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.htct.2018.10.002_bib0225","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.htct.2018.10.002_bib0230","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0235","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","article-title":"Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases","volume":"127","author":"Hosler","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.htct.2018.10.002_bib0240","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"French Reference Center for Thrombotic Microangiopathies. Unexpected frequency of Upshaw\u2013Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2141.2004.05217.x","article-title":"Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Peyvandi","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.htct.2018.10.002_bib0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2018.10.002_bib0255","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2000.01941.x","article-title":"Management of thrombotic thrombocytopenic purpura","volume":"109","author":"Rock","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.htct.2018.10.002_bib0260","first-page":"407","article-title":"Recent advances in thrombotic thrombocytopenic purpura","volume":"2004","author":"Sadler","year":"2004","journal-title":"ASH Educ Book"},{"key":"10.1016\/j.htct.2018.10.002_bib0265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0270","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1538-7836.2003.00385.x","article-title":"Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods","volume":"1","author":"Studt","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.htct.2018.10.002_bib0275","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2004-06-2096","article-title":"Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS-13 inhibitor: in vitro inhibition of ADAMTS-13 activity by hemoglobin","volume":"105","author":"Studt","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0280","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1538-7836.2004.00879.x","article-title":"Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas","volume":"2","author":"Tripodi","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.htct.2018.10.002_bib0285","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0290","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS-13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.10.002_bib0295","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.htct.2018.10.002_bib0300","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.htct.2018.10.002_bib0305","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/vox.12050","article-title":"Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort","volume":"105","author":"Bentley","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.htct.2018.10.002_bib0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.htct.2018.10.002_bib0315","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2018.10.002_bib0320","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.htct.2018.10.002_bib0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.htct.2018.10.002_bib0330","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137919300148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137919300148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:31:15Z","timestamp":1762867875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137919300148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2531137919300148"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2018.10.002","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2018.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Editora Ltda. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}]}}